Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Cathalijne C.B. Post, MD,* Stephanie M. de Boer, MD, PhD,* Melanie E. Powell, MD, PhD,† Linda Mileshkin, MD, PhD,† Dionysssios Katsaros, MD, PhD § Paul Bessette, MD, PhD,‖ Christine Haie-Meder, MD, PhD,§ Nelleke (P.) B. Ottevanger, MD, PhD,§ Jonathan A. Ledermann, MD, PhD,** Pearly Khaw, MD, PhD,†† Romerai D’Amico, MD, PhD,∗ Anthony Fyles, MD, PhD,§§ Marie Hélène Baron, MD, PhD,||| Henry C. Kitchener, MD, PhD,¶¶ Hans W. Nijman, MD, PhD,## Ludy C.H.W. Lutgens, MD, PhD,*** Susan Brooks, MD, PhD,††† Ina M. Jürgenliemk-Schulz, MD, PhD,‡‡‡ Amanda Feeney, MSc,** Geraldine Goss, MD, PhD,§§§ Roldano Fossati, MD,¶¶¶ Prafull Ghatage, MD, PhD,¶¶¶ Alexandra Leary, MD, PhD,### Viet Do, MD, PhD,*****

Corresponding author: Cathalijne C.B. Post, MD; E-mail: c.c.b.post@lumc.nl

Data sharing statement: Research data are not available at this time, but will be shared at a later stage after analysis of long-term survival outcomes.

The PORTEC-3 study was supported by a grant from the Dutch Cancer Society (grant number UL2006-4168/CKTO 2006-04), the Netherlands. PORTEC 3 was supported in the United Kingdom by Cancer Research UK (grant number C7925/A8659). Participation in the PORTEC-3 trial by the Australia and New Zealand Gynaecologic Oncology Group (ANZGOG) and the Trans-Tasman Radiation Oncology Group (TROG) was supported by the NHMRC Project (grant number 570894, 2008) and by a Cancer Australia Grant (awarded through the 2011 round of the priority-driven Collaborative Cancer Research Scheme and funded by Cancer Australia). Participation by the Italian MaNGO group was partly supported by a grant from the Italian Medicines Agency AIFA (grant number FARM4BCX2). Canadian participation in the PORTEC-3 trial was supported by the Canadian Cancer Society Research Institute (grant numbers 015469, 021039).

Disclosures: C.L.C. reports grants from Dutch Cancer Society, and other from Aduro, nonfinancial support from Merck, grants and other from DCPPrime, and nonfinancial support from Bionovion, outside the submitted work. P.B. reports grants and personal fees from Canadian Cancer Trials Group (CCTG), during the conduct of the study and outside the submitted work. R.N. reports grants from Elekta, Varian, and Accuray, outside the submitted work. All other authors declare no competing interests in relation to this study.

Supplementary material for this article can be found at https://doi.org/10.1016/j.ijrobp.2020.10.030.

Acknowledgments—We thank all the participating groups: DGOG (the Netherlands), NCRI (United Kingdom), ANZGOG (Australia and New Zealand), MaNGO (Italy), Fedegyn (France), and the Canadian Cancer Trials Group (Canada) and their coordinating teams, principal investigators, staff, and clinical research teams at the groups’ participating centers for all their work and effort. We especially thank all women who greatly contributed by repeatedly filling in the questionnaires throughout the study years. The PORTEC-3 trial involved a strong international collaboration within the Gynaecological Oncology InterGroup (GCIG), and the support of the GCIG officers and member groups is gratefully acknowledged. We also thank the members of the data safety monitoring board for their invaluable work and guidance throughout the duration of the trial.
Andrea A. Lissoni, MD, PhD,††† Mary McCormack, MD, PhD,†††
Remi A. Nout, MD, PhD,* Karen W. Verhoeven-Adema, PhD,§§§§
Vincent T.H.B.M. Smit, MD, PhD,‡‡‡‡ Hein Putter, PhD,‡‡‡‡
and Carien L. Creutzberg, MD, PhD*
Introduction

The majority of endometrial cancers are diagnosed at an early stage, but 15% to 20% of women with endometrial cancer present with high-risk disease. These high-risk cancers are characterized by higher grade, advanced stage, or nonendometrioid histology. In contrast to the favorable prognosis of most early-stage endometrial cancers, the high-risk group has an increased incidence of distant metastases and cancer-related death. Adjuvant pelvic radiation therapy has been the standard of care for these patients to maximize locoregional control1; however, chemotherapy could reduce distant metastases.

The randomized PORTEC-3 trial was initiated to evaluate the benefit of combined adjuvant pelvic radiation therapy and chemotherapy versus pelvic radiation therapy alone for women with high-risk endometrial cancer. The updated survival analysis of the PORTEC-3 trial showed a significant benefit in 5-year overall survival and failure-free survival with absolute improvement of, respectively, 5% (81% vs 76%, hazard ratio 0.70, P = .034) and 7% (76% vs 69%, hazard ratio 0.70, P = .016) after chemoradiation therapy. Patients with serous cancers and those with stage III disease were shown to benefit most from the addition of chemotherapy (absolute overall survival improvement of 19% and 10%, respectively, and failure-free survival improvement of 12% and 13%).2 For each individual patient, the potential survival benefit of chemotherapy should be weighed against the costs of longer treatment duration, increased toxicity, and influence on health-related quality of life (HRQOL).

Pelvic radiation therapy is associated with risks of long-term urinary urgency and incontinence, and bowel symptoms such as diarrhea and fecal leakage, as well as lower physical and role functioning.3-11 In the analysis of short-term toxicity and HRQOL in the PORTEC-3 trial, the addition of chemotherapy was shown to worsen the toxicity profile with more severe adverse events (AE) and impaired HRQOL during and after chemoradiation therapy. However, rapid recovery was seen; from 12 months onward there was no between-group difference in grade 3 to 4 toxicity, and grade 2 or higher sensory neuropathy was the main persistent AE at 24 months in 10% after chemoradiation therapy.1 Several studies have reported a negative correlation between chemotherapy-induced peripheral neuropathy (CIPN) and physical functioning or HRQOL.6-11 The present analysis was performed to establish long-term AE and patient-reported HRQOL for up to 5-year follow-up in women with high-risk endometrial cancer treated in the PORTEC-3 trial. The secondary objective was to evaluate whether specific conditions are correlated to HRQOL.

Methods and Materials

Patient population and study design

Details of this open-label, multicenter, randomized phase 3 trial have been reported previously.2,5,12 Briefly, patients were enrolled at 103 centers through 6 clinical trial groups. Patients were eligible if they had high-risk endometrial cancer, defined as histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) 2009 stage I endometrioid endometrial cancer grade 3 with myometrial invasion or lymph-vascular space invasion; stage II or III endometrioid endometrial cancer; or stage I to III serous or clear-cell histology. Surgery consisted of hysterectomy with bilateral salpingo-oophorectomy; clinically suspicious pelvic or periaortic lymph nodes were removed, but lymphadenectomy was not mandatory. Patients were randomly assigned (1:1) to receive pelvic radiation therapy (48.6 Gy in 1.8 Gy fractions, with a brachytherapy boost in case of cervical stromal involvement) or chemoradiation therapy (2 cycles of cisplatin 50 mg/m² in weeks 1 and 4 of radiation therapy, followed by 4 cycles of carboplatin AUC5 and paclitaxel 175 mg/m² at 3-week intervals). The study was approved by the Dutch Cancer Society and ethics committees of participating groups.

Study outcome measures

A prespecified secondary objective of the PORTEC-3 trial was to assess AE (grade ≥2 irrespective of study treatment, according to Common Terminology Criteria for Adverse Events [CTCAE] version 3.0) and for mild toxicities (grade 1) HRQOL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), the cervix 24 (CX24) module, and added neuropathy subscale and other chemotherapy side effect subscale items from the ovarian 28 (OV28) module.13,14 These were used because the EORTC endometrial module was not yet available at the time of study design. HRQOL questionnaires were completed at baseline (after surgery), after radiation therapy, and at 6, 12, 18, 24, 36, and 60 months from randomization and were discontinued upon diagnosis of recurrence or death. For all items, Likert-type response scales were used ranging from 4 to 7 points. Higher scores on functional and global HRQOL scales represented better levels of functioning. Higher scores on symptom subscales reflected higher levels of symptoms.

Statistical analysis

We used χ² statistics or the Fisher exact test for categorical variables and the t test or Mann-Whitney U test for
continuous variables to compare patient and tumor characteristics (significance $P$ value < .05).

No specific power calculations were done for toxicity and HRQOL analysis. However, the sample size ensured sufficient power to detect clinically relevant differences. Toxicity and HRQOL were analyzed according to treatment received. The prevalence of toxicity was calculated at each timepoint (using the maximum grade scored) and compared between the 2 treatment groups by the Fisher exact test.

Patients who completed baseline and at least 1 follow-up questionnaire were evaluable for HRQOL analysis. Missing data were handled as missing at random. As in previous analysis, a prespecified HRQOL analysis was done according to the EORTC Quality of Life Group guidelines.5,15 A linear mixed model was used to obtain estimates for the EORTC QLQ-C30, CX 24, and OV 28 subscales at each of the timepoints, with patient as random effect and time (categorical), treatment, and their interaction as fixed effects. Single items were analyzed with generalized mixed models (binary) logistic regression with the same random and fixed effects as in the linear mixed model, combining scores of 1 to 2 (“not at all” and “a little”) and 3 to 4 (“quite a bit” and “very much”). Additional linear mixed models were used within treatment arms with time, age, and their interaction as fixed effects. The difference in HRQOL between the groups over time was tested by a joint Wald test of all treatment-by-time interaction in the linear or logistic mixed model. Age-matched normative population means16,17 were compared with both treatment groups using the $t$ test. General population normative data of more than 1500 women across Europe and North America aged 60 to 69 years16 were used for the EORTC QLQ-C30 scales, and general Dutch population normative data of 87 women aged 61 to 70 years were used for sexuality items.17

Guidelines on the interpretation of clinically relevant between-group differences in EORTC QLQ-C30 scores were applied (trivial, small, medium, or large differences per scale).18 An additional post hoc analysis was performed to assess long-term (3-year and 5-year mean) changes from baseline at individual level. Between-group differences on scales not included in the guidelines and long-term changes were assessed according to Osoba et al.19 Improvement and deterioration were defined respectively as a ≥10-point increase or decrease, and a stable score was defined as a <10-point change. Changes were compared between treatment groups using the Fisher exact test. In addition, Kendall’s rank correlation was used post hoc to measure the ordinal association between different HRQOL items and scales. Finally, stepwise binary logistic regression with likelihood ratio test–based backward selection was performed to identify risk factors for developing tingling/numbness, including diabetes, cardiovascular disease, hypertension, age (≥70 years), type of surgery, performance status, and chemotherapy compliance.

To guard against false-positive results due to multiple testing, a 2-sided $P$ value ≤ .01 was considered statistically significant, and $P$ values < .05 were reported as a trend. Statistical analyses were done with SPSS, version 25, and R, version 3.6.1.

Results

Study population and compliance

The PORTEC-3 trial accrued 660 eligible patients between 2006 and 2013; 333 patients received radiation therapy alone and 327 patients received chemoradiation therapy. At the time of analysis, median follow-up was 74.6 months (interquartile range, 60-86). Patient and treatment characteristics were well balanced between the groups (Table 1).

Baseline questionnaires and at least 1 follow-up questionnaire were received from 574 (87%) patients (292 in the chemoradiation therapy group and 282 in the radiation therapy-alone group). At 3 years, the completion rate was 89%, and at 5 years it was 63% (Table E1). Age distribution remained constant over time (data not shown). World Health Organization performance score differed between responders and nonresponders at baseline, with a score of ≥2 in 5 (1%) of the 574 responders versus 5 (6%) of the 86 nonresponders ($P = .005$, Table E3). At baseline, 88% of the responders had completed all items of the EORTC QLQ-C30, 83% all items of the CX24 subscales, 95% all nonsexual items, and 91% all items of the OV28 subscale.

Adverse events

AE reported over time are summarized in Table 2 and Figure 1. At baseline (after surgery), no significant between-group differences were found; grade ≥2 baseline AE were scored for 143 (44%) patients in the chemoradiation therapy group and 124 (37%) patients in the radiation therapy group. The most frequently scored AE was hypertension (27%). At 5 years, grade ≥2 AE were reported for 78 (38%) patients who had received chemoradiation therapy versus 46 (24%) patients who had received radiation therapy ($P = .008$); grade ≥2 sensory neuropathy persisted in 13 (6%) after chemoradiation therapy versus none after radiation therapy alone ($P < .001$). Other grade ≥2 AE did not significantly differ between groups at 5 years, including hypertension in 10% and urinary incontinence in 5% in both groups. Urinary urgency was reported in 9 (4%) versus 3 (2%) patients after chemoradiation therapy versus radiation therapy; any gastrointestinal toxicity in 17 (8%) versus 11 (6%), including diarrhea in 9 (4%) versus 7 (3%) and pain in 18 (9%) versus 9 (5%); and most often arthralgia in 11 (5%) versus 5 (3%). Grade 3 AE did not differ significantly between the groups at 5 years (5% vs 8%, $P = .18$), and only 1 new grade 4 AE was reported (ileus obstruction requiring surgery 5 years after chemoradiation therapy).
clinically relevant differences were found for physical and role functioning (Fig. 2A, 2B). At 3 years, mean scores were 79 versus 87 ($P < .001$) for physical functioning and 78 versus 88 ($P < .001$) for role functioning after chemoradiation therapy and radiation therapy, respectively; these scores were trivially different from the age-matched normative population.

Long-term global health/QOL scores were not statistically or clinically different between the treatment groups. However, small to medium clinically relevant better scores were seen in the PORTEC-3 study population compared with the normative population (Fig. 2C). Trends for worse long-term pain and fatigue symptom scores after chemoradiation therapy were seen, with the largest difference at 3 years (20.5 vs 14.1, $P = .008$; 26.0 vs 20.7, $P = .015$, respectively); these were small but clinically relevant differences (Fig. E2). No long-term significant differences in social, cognitive, and emotional functioning were found between treatment groups or in comparison to the normative population (Fig. E1).

Among patients who had received chemoradiation therapy, age groups (<70 vs ≥70 years) differed in their change in scores over time for physical functioning ($P < .001$), role functioning ($P = .011$), global health/QOL ($P < .001$), pain ($P = .004$), and fatigue ($P = .002$); being more unfavorable in older patients. This also applies within the radiation therapy group for the physical and role functioning scores ($P < .01$), although not for global health/QOL ($P = .42$), pain ($P = .33$), and fatigue ($P = .19$). Data are displayed in Figure E3.

### Symptom items

A complete overview of the proportion of patients reporting significant (“quite a bit” or “very much”) symptoms is shown in supplementary Table E2. Patients treated with chemoradiation therapy reported more significant tingling or numbness throughout the 5-year follow-up period compared with patients who received radiation therapy alone. At 5 years, 32 (24%) patients treated with chemoradiation therapy reported significant tingling or numbness, in contrast to 9 (9%) treated with radiation therapy ($P = .002$). Likewise, 129 (62%) versus 66 (40%) patients had deteriorated in tingling/numbness compared with baseline ($P < .001$, Fig. 3 and Fig. E5A); no difference between patients with or without diabetes was found among patients treated with chemotherapy (Fig. E4C and E5B). A trend toward worse tingling/numbness in patients aged ≥70 years was found over time after chemoradiation therapy ($P = .016$) but not after radiation therapy ($P = .35$, Fig. A4 B). None of variables entered in the multivariate logistic regression model were statistically significant risk factors for tingling/numbness (data not shown).

### HRQOL subscales

Results of the EORTC QLQ-C30 functioning and global health/quality of life (QOL) subscales and CX24 and OV28 subscales are summarized in Table 3. Up to 3 years, small clinically relevant differences were found for physical and...
### Table 2

Adverse events reported by physicians using CTCAE v3.0 during treatment and at 3- and 5-year follow-up

|                      | Grade 2 | Grade 3/4 | At 3 years | Grade 2 | Grade 3/4 | At 5 years | Grade 2 | Grade 3/4 | At 5 years |
|----------------------|---------|-----------|------------|---------|-----------|------------|---------|-----------|------------|
|                      | CTRT n = 327 | RT n = 333 | P | CTRT n = 269 | RT n = 277 | P | CTRT n = 207 | RT n = 193 | P |
| Any                  | 110 (34) | 103 (31) | <.01 | 198 (61) | 41 (12) | <.01 | 63 (23) | 49 (18) | .04 |
| Any grade 3          | na      | na        |     | na      | na        |     | na      | na        |     |
| Any grade 4          | na      | na        |     | 50 (15) | 0 (0)     |     | 1 (0)   | 0 (0)     |     |
| Hypertension         | 19 (6)  | 12 (4)    | .10 | 6 (2)   | 3 (1)     | .34 | 15 (6)  | 17 (6)    | .75 |
| Lymphatics (edema)   | 7 (2)   | 4 (1)     | .17 | 2 (1)   | 0 (0)     | .25 | 3 (1)   | 1 (0)     | .12 |
| Gastrointestinal, any| 145 (44)| 79 (24)   | <.01| 47 (14) | 18 (5)    | <.01| 11 (4)  | 7 (6)     | .46 |
| Diarrhea             | 103 (31)| 68 (20)   | <.01| 35 (11) | 14 (4)    | <.01| 4 (1)   | 8 (3)     | .42 |
| Ileus/obstruction    | 3 (1)   | 5 (2)     | .77 | 2 (1)   | 2 (1)     | 1.00| 0 (0)   | 0 (0)     | .49 |
| Hematological, any   | 100 (31)| 19 (6)    | <.01| 149 (46)| 18 (5)    | <.01| 3 (1)   | 3 (1)     | 1.00 |
| Lymphocytes          | 48 (15)| 16 (5)    | <.01| 109 (33)| 17 (5)    | <.01| 1 (0)   | 0 (0)     | 1.00 |
| Neuropathy, any      | 82 (25)| 1 (0)     | <.01| 23 (7)  | 0 (0)     | <.01| 18 (7)  | 2 (1)     | <.01 |
| Neuropathy, motor    | 13 (4)  | 1 (0)     | <.01| 4 (1)   | 0 (0)     | .06 | 3 (1)   | 2 (1)     | .44 |
| Neuropathy, sensory  | 79 (24)| 0 (0)     | <.01| 22 (7)  | 0 (0)     | <.01| 18 (7)  | 1 (0)     | <.01 |
| Pain, any            | 101 (31)| 23 (7)    | <.01| 31 (9)  | 4 (1)     | <.01| 17 (6)  | 15 (5)    | .30 |
| Arthralgia           | 52 (16)| 2 (1)     | <.01| 10 (3)  | 0 (0)     | <.01| 2 (1)   | 5 (2)     | .73 |
| Muscle pain          | 52 (16)| 1 (0)     | <.01| 9 (3)   | 0 (0)     | <.01| 3 (1)   | 0 (0)     | .12 |
| Back/pelvic/limbs    | 10 (3)  | 4 (1)     | <.01| 11 (3)  | 0 (0)     | <.01| 4 (1)   | 3 (1)     | .50 |
| Abdomen/cramps       | 14 (4)  | 9 (3)     | .28 | 4 (1)   | 4 (1)     | 1.00| 5 (2)   | 1 (0)     | .07 |
| Musculoskeletal (other)| 2 (1)   | 2 (1)    | .50 | 2 (1)   | 0 (0)     | .50 | 1 (0)   | 0 (0)     | .24 |
| Pulmonary, dyspnea   | 14 (4)  | 2 (1)     | .25 | 5 (2)   | 0 (0)     | .03 | 1 (0)   | 0 (0)     | 1.00 |
| Genitourinary        | 12 (4)  | 5 (2)     | .06 | 1 (0)   | 0 (0)     | .50 | 8 (3)   | 3 (1)     | .09 |
| Urinary urgency      | 24 (7)  | 10 (3)    | .01 | 2 (1)   | 2 (1)     | 1.00| 7 (3)   | 5 (2)     | .57 |
| Constitutional Fatigue| 69 (21)| 7 (2)     | <.01| 10 (3)  | 0 (0)     | <.01| 1 (0)   | 0 (0)     | .49 |

Adverse events were calculated at each timepoint. Per adverse event, the maximum grade per patient was calculated (worst ever by patient). For grade 2, 3, and 4 adverse events, P values < .01 were deemed significant.

**Abbreviations:** CTCAE v3.0 = Common Terminology Criteria for Adverse Events version 3.0; CTRT = combined chemotherapy and radiation therapy; RT = radiation therapy.
Chemoradiation therapy patients reported more significant limb weakness up to 3 years (21% after chemoradiation therapy vs 5% after radiation therapy at 3 years, \( P < .001 \)), with deterioration at 3 and 5 years compared with baseline in 92 (44%) patients after chemoradiation therapy versus 46 (28%) after radiation therapy (\( P = .003 \), Fig. 3). No between-group differences in long-term change of gastrointestinal and bladder symptoms were seen (Fig. 3).

Sexual activity did not differ between the 2 treatment groups at 3 and 5 years (Table E2). Sexual activity was reported by 69 (34%) patients (both treatment groups combined) at 5 years. Among those sexually active, 14 (19%) patients reported significant pain during sex; 20 (27%) reported significant vaginal dryness, and 58 (80%) reported sex to be enjoyable. Mean sexual activity scores were lower than those of the age-matched normative population, with a clinically relevant moderate difference (\( P < .001 \); Fig. E6).

Correlation

The strongest between-functioning score correlations were found for physical and role functioning (\( \tau = 0.66 \)), for social and role functioning (\( \tau = 0.61 \)), for global health/QOL and role functioning (\( \tau = 0.58 \)), and for global health/QOL and physical functioning (\( \tau = 0.53 \)). The strengths of the negative correlations between symptoms and functioning varied from \(-0.12\) to \(-0.64\), with the strongest correlation for fatigue, closely followed by pain, limb weakness, muscle/joint pain, and lower back pain. The correlation between these symptoms also was relatively strong (\( \tau = 0.39-0.55 \)). Finally, there were significant negative correlations for tingling/numbness and physical functioning (\( \tau = -0.32 \)), role functioning (\( \tau = -0.30 \)), global health/QOL (\( \tau = -0.26 \)), and the other functioning scales (\( \tau = -0.22 \) to \(-0.25 \)). A comprehensive correlation matrix is displayed in Figure E7.

Discussion

This long-term analysis of toxicity and HRQOL in the PORTEC-3 trial shows that combined adjuvant chemotherapy and radiation therapy for high-risk endometrial cancer may have a long-lasting clinically relevant negative impact on QOL, with a small long-term deterioration in physical and role functioning for the first 3 years after treatment compared with radiation therapy alone. Patients treated with chemoradiation therapy reported significantly more prominent limb weakness until 3 years and persistent tingling or numbness in hands or feet throughout the 5-year follow-up period. In addition, more grade \( \geq 2 \) toxicity was reported at 5 years (38% vs 24%). Despite these persistent symptoms, the treatment groups had similar long-term global health/QOL scores that were in fact better than those of the age-matched normative population. This is the first comprehensive documentation of long-term patient-reported symptoms and HRQOL after chemoradiation therapy in endometrial cancer, with the strength of comparison to pelvic radiation therapy alone and to an age-matched normative population, exclusion of biases due to the randomization, and complete follow-up. These data are essential for patient counseling and shared decision making on adjuvant therapy in high-risk endometrial cancer.

The present study found remaining grade \( \geq 2 \) sensory neuropathy in 6% after chemoradiation therapy, with HRQOL showing “quite a bit” or “very much” tingling/numbness being reported by 24% at 5 years. The recovery

![Fig. 1](https://example.com/fig1.png)

**Fig. 1.** Incidence of the maximum physician-reported adverse event grades per patient for each timepoint at baseline, during treatment, at 6-month follow-up, and at 1-, 2-, 3-, and 5-year follow-up after pelvic radiation therapy alone (A) and combined pelvic radiation therapy and chemotherapy (B).
was largest in the first months after chemotherapy and improved until 2 years to a stable level. In comparison, less than 10% of the patients reported long-term significant tingling/numbness after radiation therapy alone (no reported grade ≥ 2 AE), which seemed most likely due to diabetic and idiopathic peripheral neuropathy in this elderly population.  

Because limited agreement between patient

and physician scoring of toxicities has been reported, physicians were required to report grade ≥2 AE to focus on more severe toxicities, whereas patient-reported outcomes were used for milder toxicities. Reported data on long-term toxicity and HRQOL of women treated with carboplatin and paclitaxel chemotherapy, although limited, are available from trials of first-line therapy in ovarian cancer.

---

Table 3  Patient-reported health-related quality of life using the EORTC QLQ-C30 and subscales of CX-24 and OV-28

| Questionnaire time points | After | Months | P value | Norm |
|---------------------------|-------|--------|---------|------|
|                           | Baseline | RT | 6 | 12 | 36 | 60 | Time | Tx | Time | Tx | Tx | 60-69 yr | CS |
| EORTC-QLQ C30             |         |     |       |       |     |   |     |     |     |     |     |     |     |
| EORTC functioning scales  |         |     |       |       |     |   |     |     |     |     |     |     |     |
| Physical functioning      | CTRT    | 81.3 | 76.0 | 72.6 | 79.9 | 79.4 | 81.4 | <.001 | <.001 | <.001 | .31  | 82.1 | T   |
|                          | RT      | 84.5 | 83.3 | 86.5 | 86.6 | 86.6 | 83.5 | .001  | <.001 | <.001 | T    |     |     |
| Role functioning         | CTRT    | 69.9 | 66.5 | 67.3 | 79.3 | 78.3 | 84.5 | <.001 | <.001 | <.001 | .0007 | .40  | 83.5 | T   |
|                          | RT      | 73.6 | 74.1 | 84.6 | 86.0 | 88.0 | 87.4 | <.001 | <.001 | <.001 | T    |     |     |
| Emotional functioning     | CTRT    | 74.4 | 76.9 | 77.0 | 80.7 | 81.6 | 84.6 | <.001 | .14   | <.001 | .33  | .80  | 77.8 | S   |
|                          | RT      | 77.4 | 81.5 | 80.8 | 82.7 | 83.5 | 84.0 | <.001 | .0022 | .035  | .18  | .66  | 87.9 | T   |
| Cognitive functioning     | CTRT    | 86.9 | 81.4 | 79.4 | 83.8 | 83.4 | 86.8 | <.001 |        | .0002 | .37  | .054 | 65.6 | S   |
|                          | RT      | 87.9 | 85.8 | 86.9 | 87.3 | 86.4 | 87.8 | <.001 |        | <.001 | .37  | .054 | 65.6 | S   |
| Social functioning        | CTRT    | 77.7 | 73.5 | 74.0 | 84.2 | 85.4 | 90.2 | <.001 | <.001 | <.001 | .43  | .72  | 88.1 | T   |
|                          | RT      | 80.1 | 78.7 | 88.1 | 89.9 | 87.2 | 91.2 | <.001 | <.001 | <.001 | T    |     |     |     |
| Global health status/ QOL | CTRT    | 69.3 | 60.3 | 65.0 | 72.8 | 73.8 | 74.4 | <.001 | <.001 | <.001 | .37  | .054 | 65.6 | S   |
|                          | RT      | 70.6 | 68.7 | 72.6 | 74.0 | 75.7 | 79.2 | <.001 | <.001 | <.001 | .37  | .054 | 65.6 | S   |
| EORTC symptom scales      |         |     |       |       |     |   |     |     |     |     |     |     |     |     |
| Fatigue                   | CTRT    | 29.0 | 24.4 | 38.4 | 28.2 | 26.0 | 23.3 | <.001 | <.001 | <.001 | .015 | .058 | 26.6 | T   |
|                          | RT      | 26.6 | 34.4 | 23.8 | 22.8 | 20.7 | 18.4 | <.001 | <.001 | <.001 | S    |     |     |     |
| Nausea and vomiting       | CTRT    | 3.7  | 14.1 | 9.1  | 5.1  | 3.7  | 4.2  | <.001 | <.001 | <.001 | .67  | .81  | 3.7  | T   |
|                          | RT      | 4.0  | 10.2 | 5.7  | 6.1  | 4.3  | 3.8  | <.001 | <.001 | <.001 | T    |     |     |     |
| Pain                      | CTRT    | 18.4 | 21.6 | 23.5 | 21.1 | 20.5 | 16.2 |        | <.001 | <.001 | .0075 | .34  | 25.4 | S   |
|                          | RT      | 17.1 | 19.1 | 16.9 | 15.6 | 14.1 | 13.5 | <.001 | <.001 | <.001 | <.001 | .31  | 25.4 | S   |
| CX 24 subscales/items     |         |     |       |       |     |   |     |     |     |     |     |     |     |     |
| Symptom experience        | CTRT    | 9.7  | 16.2 | 12.2 | 11.8 | 12.3 | 12.1 | <.001 | <.001 | .6    | .0047 | .56  | .59  |     |
|                          | RT      | 9.5  | 16.9 | 11.8 | 12.5 | 11.7 | 11.5 | <.001 | <.001 | <.001 | S    |     |     |     |
| Body image                | CTRT    | 12.0 | 17.2 | 25.3 | 16.9 | 16.4 | 13.7 | <.001 | <.001 | <.001 | .0053 | .25  |     |     |
|                          | RT      | 10.0 | 13.1 | 13.0 | 11.9 | 10.6 | 11.1 | <.001 | <.001 | <.001 | T    |     |     |     |
| Sexual functioning        | CTRT    | 14.3 | 21.3 | 19.0 | 20.4 | 23.4 | 25.3 | .059  | .53   | <.001 | .83  | .92  |     |     |
|                          | RT      | 11.5 | 23.2 | 22.5 | 24.3 | 26.0 | 26.2 | <.001 | <.001 | <.001 | S    |     |     |     |
| OV 28 subscales           |         |     |       |       |     |   |     |     |     |     |     |     |     |     |
| Chemotherapy              | CTRT    | 6.2  | 18.9 | 31.7 | 14.9 | 14.6 | 14.9 | <.001 | <.001 | <.001 | .0083 | .061 |     |     |
|                          | RT      | 7.8  | 11.0 | 12.1 | 11.5 | 10.8 | 11.7 | <.001 | <.001 | <.001 | R    |     |     |     |
| Peripheral neuropathy     | CTRT    | 5.5  | 14.8 | 47.1 | 32.4 | 28.8 | 23.5 | <.001 | <.001 | <.001 | .001 | .0032 |     |     |
|                          | RT      | 5.5  | 8.7  | 12.5 | 11.3 | 13.6 | 16.3 | <.001 | <.001 | <.001 | T    |     |     |     |

All subscales responses were converted to 0 to 100 scales (according to the EORTC guidelines). Higher scores for functioning items and global health status/quality of life scale represent a better level of functioning. For the symptom scales, a higher score reflects a higher level of symptoms. P values <.01 for treatment comparison were deemed significant.

Abbreviations: CS = clinical significance at 5 years; CX = cervix; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer quality of life questionnaire C30; CTRT = combined chemotherapy and radiation therapy; HRQOL = health-related quality of life; NM = medium difference; Norm = age-match normative data based on women aged 60 to 69 years across 13 European countries, Canada, and the United States; OV = ovarian; P time = changes of quality-of-life scores over time; P Tx = difference between the 2 treatment groups; P Tx at 3 y = difference between the 2 treatment groups at 3 years; P Tx at 5 y = difference between the 2 treatment groups at 5 years; P time by Tx = difference between the 2 treatment groups over time; RT = radiation therapy; Tx = treatment; S = small difference; T = trivial difference.

* Clinically relevant small difference.
† Clinically relevant medium difference.
‡ Items included in the subscale are specified in supplementary Table E2.
This comparison is relevant because patients with ovarian cancer are of similar age and had previous pelvic surgery without radiation therapy. Similar levels of patient-reported persistent tingling/numbness with a comparable pattern of recovery after chemotherapy were seen in studies of ovarian cancer survivors. The randomized GOG-249 trial, in which 3 cycles of carboplatin and paclitaxel with vaginal brachytherapy were compared with pelvic radiation therapy alone in women with high-intermediate and high-risk stage I-II endometrial cancer, also showed significantly higher CIPN rates in the chemotherapy arm (sensory neuropathy grade ≥2 in 10% at 2 years), even while using only 3 cycles. Detailed analysis on HRQOL in the GOG-249 trial is pending.

Another important persistent symptom after chemoradiation therapy was limb weakness, which might be interpreted as a result of motor CIPN. However, limb weakness was found to be more strongly correlated to fatigue and muscle/joint pain than to tingling/numbness; this finding supports previous studies suggesting that limb weakness is more a general symptom, associated with fatigue and reduced physical functioning. The correlation coefficient (τ = 0.32) found between tingling/numbness and physical functioning means that a patient with a higher tingling/numbness score had a 66% chance of also having a worse functioning score compared with another patient. This suggests that tingling/numbness is associated with impaired functioning, although correlations for other symptoms (limb weakness, fatigue, and pain) and functioning and global health/QOL were stronger. Most nonlongitudinal studies investigating the correlation between sensory neuropathy and functioning in various cancer types found a negative correlation. Bonhof et al. found significant functioning differences between patients with and without limb weakness, but not for tingling/numbness at 2 years, possibly due to the small sample size. In general, it seems that functioning is negatively influenced by several symptoms, including tingling/numbness, limb weakness, fatigue, and pain.

In this long-term analysis, it seemed that chemoradiation therapy patients further improved between 3 and 5 years of follow-up in physical and role functioning and limb weakness. It is possible that the relatively high attrition rate (around 30%) between 3 and 5 years might introduce some response bias. A small part of the attrition at this timepoint is explained by death or recurrence; however, other reasons for missing questionnaires were not collected. Notably, chemoradiation therapy patients who responded only at 3 years reported significantly more significant muscle/joint pain, symptoms that were strongly correlated to physical and role functioning, than patients who responded both at 3 and 5 years. Another explanation could be that patients adjust their lives to bothersome but manageable symptoms, which is also suggested by the improvement in long-term

Fig. 2. Patient functioning on subscales from European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 for physical functioning (A), role functioning (B), and global health status/quality of life (C). A higher score indicates a higher level of functioning. Error bars show 95% confidence interval. Abbreviations: CT = chemotherapy; Norm = mean scores of age-match normative data based on women aged 60 to 69 years across 13 European countries, Canada, and the United States; P time by treatment = difference between the 2 treatment groups over time; P 3yrs by treatment = difference between the 2 treatment groups at 3 years; P 5yrs by treatment = difference between the 2 treatment groups at 5 years; RT = radiation therapy; QOL = quality of life.
Moreover, possible bias due to the Hawthorne effect should be taken into consideration when comparing normative to trial population data; patients participating in trials may report better QOL than normative populations.

One limitation of the study is that toxicity, even though scored by a physician according to the CTCAE classification, remains a subjective measurement. At baseline, grade ≥2 hypertension was scored in 27% of the patients, corresponding to the on-study form reporting 33% patients having hypertension with medication. At subsequent timepoints, hypertension was only scored in about 10% of the patients. This implies that during and after therapy, oncologists focus on treatment-related AE, resulting in underreporting of unrelated conditions primarily managed by family doctors such as hypertension, which is especially important in interpreting changes from baseline. Because the bias occurred in both groups, it has negligible impact on long-term between-group comparison.

The contemporary challenge is to avoid significant symptoms caused by chemotherapy by developing preventive strategies and intervention measures. Unfortunately, there is currently no effective treatment or prevention strategy against CIPN. This study was unable
to identify risk factors for persistent CIPN, which is unfortunate because data on risk factors for developing CIPN are inconsistent. Limitations to drawing any conclusion include the selected study population based on inclusion criteria and insufficient power related to small groups. Nevertheless, patients aged 70 years or older scored generally worse over time than younger patients, even though this was a selected population of relatively fit women. This age-based difference, particularly for global health/QOL and symptoms of pain, fatigue and tingling/numbness is more pronounced after chemoradiation therapy compared with radiation therapy. Older patients seemed to have a relatively greater failure-free survival benefit from chemotherapy. Therefore, specific patient counseling is recommended for older patients.

No between-group differences were found for gastrointestinal and bladder symptoms, largely explained by the use of pelvic radiation therapy in both arms. The reported gastrointestinal symptoms (eg, urgency and diarrhea in about 10% of the patients) and bladder symptoms (urgency ±25%, incontinence ±10%) are consistent with the rates found after pelvic radiation therapy in the PORTEC-2 trial. The incidence of gastrointestinal symptoms is expected to remain more or less stable, and urinary symptoms are expected to slightly deteriorate in the following years owing to the combined effects of radiation therapy and aging on the pelvic floor and bladder.

The overall survival benefit of chemoradiation therapy compared with radiation therapy alone in high-risk endometrial cancer was 5% at 5 years for the complete trial population, with the greatest benefit of ≥10% observed in women with serous cancers and those with stage III disease. Molecular classification can be used to more effectively identify subgroups that benefit most from chemotherapy. For example, molecular classification in clinical diagnostics might lead to the specific recommendation of chemoradiation therapy in those with TP53-mutated tumors, and chemotherapy might be omitted in POLE and mismatch repair deficient tumors. Women with high-risk mismatch repair deficient tumors might be better treated with adjuvant immunotherapy, with a different but generally more favorable toxicity profile than carboplatin-paclitaxel chemotherapy.

The trade-off between the benefit and the short- and long-term toxicities of chemotherapy should be discussed as part of shared decision making. To better guide shared decision making, it is important to know what patients consider important in this trade-off. In a patient preference study done by the ANZGOG group among their PORTEC-3 participants, more than 50% of women reported a 5% survival improvement as being sufficient to make chemotherapy worthwhile. No study to date has examined which factors are prioritized by patients and clinicians in this decision-making process and what survival improvement would be sufficient to make chemotherapy worthwhile based on the actual symptoms and HRQOL impairment in the PORTEC-3 trial. This is currently being investigated in a Dutch trade-off study in patients with high-risk endometrial cancer and their health care professionals.

Conclusions

This study shows a long-lasting, clinically relevant, negative impact of combined chemotherapy and radiation therapy on toxicity and QOL compared with radiation therapy alone, with persistent peripheral sensory neuropathy at 5 years in 24% of patients and small but clinically relevant differences in physical and role functioning until 3 years. These results provide essential information to be used for patient counseling and shared decision making.

References

1. Casado A, González-Martín A, Rodolakis A, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol 2015;27:16-41.
2. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): Patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019;20:1273-1285.
3. Nout RA, and Poll-Franse LVvd, Lybeert MLM, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011;29:1692-1700.
4. De Boer SM, Nout RA, Jurgeneit-Schulz IM, et al. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: Results from the randomized PORTEC-2 trial. Int J Radiat Oncol Biol Phys 2015;93:797-809.
5. de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk randomised, phase 3 trial. Lancet Oncol 2016;17:1-13.
6. Ezendam NP, Piijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry. GynecoL Oncol 2014;135:510-517.
7. Kober KM, Mazor M, Abrams G, et al. Phenotypic characterization of paclitaxel-induced peripheral neuropathy in cancer survivors. J Pain Symptom Manage 2018;56:908-919.e903.
8. Soveri LM, Lammimmaki A, Hanninen UA, et al. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 2019;1-9.
9. Bonhof CS, Mols F, Vos MC, et al. Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study. GynecoL Oncol 2018;149:455-463.
10. Simon NB, Danso MA, Alberico TA, et al. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res 2017;26:2763-2772.
11. Eckhoff L, Knoep A, Jensen MB, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 2015;51:292-300.
12. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international,
open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol* 2018; 19:295-309.

13. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. *Eur J Cancer* 2003;39:1402-1408.

14. Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, et al. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. *Cancer* 2006;107:1812-1822.

15. Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

16. Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality-of-life questionnaire based on 15,386 persons across 13 European countries, Canada, and the United States. *Eur J Cancer* 2019;107:153-163.

17. van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. *Eur J Cancer* 2011;47:667-675.

18. Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. *J Clin Oncol* 2011;29:89-96.

19. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998;16:139-144.

20. Visser NA, Notermans NC, Linssen RS, et al. Incidence of polyneuropathy in Utrecht, the Netherlands. *Neurology* 2015;84:259-264.

21. Maio MD, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials. *J Clin Oncol* 2015;33:910-915.

22. Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. *J Clin Oncol* 2019;37:1810-1818.

23. Cull A, Howat S, Greimel E, et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials. *Eur J Cancer* 2001;37:47-53.

24. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. *Gynecol Oncol* 2016;140:176-183.

25. Colvin LA. Chemotherapy-induced peripheral neuropathy: Where are we now? *Pain* 2019;160(Suppl 1):S1-S10.

26. Nout RA, Putter H, Jurgeniemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. *Eur J Cancer* 2012;48:1638-1648.

27. Leon-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. *J Clin Oncol* 2020;38:3388-3397.

28. On behalf of the ANZGOG and PORTEC Group, Blinman P, Mileshkin L, et al. Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. *Br J Cancer* 2016;15:1179-1185.